BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 21, 2026
Home » Topics » Briefs » Regulatory actions

Regulatory actions
Regulatory actions RSS Feed RSS

Regulatory actions for Feb. 6, 2025

Feb. 6, 2025
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adicet, Amgen, Arbor, Astellas, Gradalis, Helius, Genentech, Serac, Valneva.
Read More

Regulatory actions for February 6, 2025

Feb. 6, 2025
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Huxley Medical, Signifier Medical Technologies.
Read More

Regulatory actions for Feb. 5, 2025

Feb. 5, 2025
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Supernus.
Read More

Regulatory actions for February 5, 2025

Feb. 5, 2025
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Supernus.
Read More

Regulatory actions for Feb. 4, 2025

Feb. 4, 2025
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astrazeneca, Bioarctic, Eisai, Fondazione Telethon, Halozyme, Janssen-Cilag, Ocugen, Spur, United.
Read More

Regulatory actions for February 4, 2025

Feb. 4, 2025
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Femasys, Gyder, Rapidai.
Read More

Regulatory actions for February 4, 2025

Feb. 4, 2025
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Apellis, Akeso, Astrazeneca, Biogen, Clearside, CSL Behring, GSK, Iaso, Impact, Innovent, Junshi, Kalvista, Telix, Vyluma, Zai Lab.
Read More

Regulatory actions for Feb. 3, 2025

Feb. 3, 2025
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astrazeneca, Axsome, Bavarian Nordic, BMS, Celltrion, Daiichi Sankyo, Merck, Pfizer, Sanofi, Vertex, Viiv, Zai Lab.
Read More

Regulatory actions for February 3, 2025

Feb. 3, 2025
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bioretec, Essilorluxottica, Roche.
Read More

Regulatory actions for Jan. 31, 2025

Jan. 31, 2025
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amgen, Comanche, Dilafor, Karolinska, Ironwood, March.
Read More
Previous 1 2 … 59 60 61 62 63 64 65 66 67 … 340 341 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Wireframe of feet and scale

    GLP-1s need technologies for long-term use

    BioWorld
    For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
  • UTRN gene involved in arthrogryposis, study finds

    BioWorld Science
    Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
  • Blue-gray dollar sign

    HMNC raises $50M series B to prep depression drugs for phase III

    BioWorld
    HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing